Login / Signup

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population.

Beatriz Garcia-CañibanoSami OuanesGowrii Saswathy GanesanWajiha YousufBasel HumosTehniyat BaigFaiza IbrahimRajvir SinghDirk Deleu
Published in: Journal of drug assessment (2021)
Our real-world experience confirms good efficacy, tolerability, and safety of ocrelizumab in our Arab population.
Keyphrases
  • multiple sclerosis
  • open label
  • randomized controlled trial
  • white matter
  • study protocol
  • double blind